Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?

Yıl: 2019 Cilt: 27 Sayı: 2 Sayfa Aralığı: 77 - 86 Metin Dili: Türkçe DOI: 10.5222/jarss.2019.25743 İndeks Tarihi: 03-01-2020

Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?

Öz:
Orak hücreli anemi ve talasemi, dünyada en sık görülen kalıtsal hemoglobinopatilerdir. Kronikhemolitik anemi ile seyrederler. Yaşam kaliteleri için aralıklı kan transfüzyonuna gereksinimduyarlar. Sıklıkla dokuya oksijen sunumunda sorun yaşayan bu hastalarda erken yaşlarda çokluorgan yetmezlikleri gelişir. Kan transfüzyonunun yan etkilerini sık yaşayan ve organ fonksiyonlarısınırda olan bu hastaların anestezi yönetimleri oldukça zor ve karmaşıktır. Ne yazık ki bugünekadar hastalarda perioperatif komplikasyonların azaltılabilmesi açısından gerekli transfüzyonmiktarı ve hemoglobin düzeyleri konusunda, kanıta dayalı, ortak bir görüş oluşturulamamıştır.Literatürde varolan veriler, özellikle preoperatif döneme odaklanmış, az sayıdaki randomize kontrollü çalışmalar ve olgu sunumlarıdır. Bu derlemede orak hücreli anemi ve talasemiler ayrı başlıklar halinde ele alınmış, hemoglobinopatili hastalara uygulanan perioperatif transfüzyonlarıngereklilikleri değerlendirilmeye çalışılmıştır.
Anahtar Kelime:

Konular: Anestezi Yoğun Bakım, Tıp

Difficult Decision in Hereditary Hemoglobinopathies: Blood transfusion; when, how and why?

Öz:
Sickle cell anemia and thalassaemia are the most common hereditary hemoglobinopathies in the world. They course with chronic hemolytic anemia. These patients require intermittent blood transfusion for their quality of life. Multiple organ failure develops at an early age in these patients, who frequently experience problems in delivering oxygen to the tissue. The anesthetic management of these patients who have frequent side effects of blood transfusion and whose organ functions are at the limit is quite difficult and complicated. Unfortunately, no evidencebased, commonly shared opinion has been established about the amount of transfusion required and desired hemoglobin levels to reduce perioperative complications in these patients. The data available in the literature are derived from scarce number of randomized controlled trials and case reports, especially focused on the preoperative period. In this review, sickle cell anemia and thalassemia are treated as separate headings and the indications of perioperative transfusions applied to patients with hemoglobinopathy have been evaluated.
Anahtar Kelime:

Konular: Anestezi Yoğun Bakım, Tıp
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Malik P. Gene Therapy for hemoglobinopathies: Tremendous successes and remaining caveats. Mol Ther. 2016;24:668-70. https://doi.org/10.1038/mt.2016.57
  • Khurmi N, Gorlin A, Misra L. Perioperative considerations for patients with sickle cell disease: a narrative review. Can J Anaesth. 2017; 64:860-9. https://doi.org/10.1007/s12630-017-0883-3
  • Modell B, Darlison MW, Moorthie S, Blencowe H, Petrou M, Lawn J. Epidemiologic methods in community genetics and model global database of congenital disorders, 2016.
  • Tsaras G, Owusu-Ansah A, Boateng FO, AmoatengAdjepong Y. Complications associated with sickle cell trait: a brief narrative review. Am J Med. 2009;122:507-12. https://doi.org/10.1016/j.amjmed.2008.12.020
  • Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10:e1001484. https://doi.org/10.1371/journal.pmed.1001484
  • Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011;41:398-405. https://doi.org/10.1016/j.amepre.2011.09.013
  • Lovaglio PG. Patient safety analysis linking claims and administrative data. Int J Health Care Qual Assur. 2012;25:698-711. https://doi.org/10.1108/09526861211270640
  • Adjepong KO, Otegbeye F, Adjepong YA. Perioperative management of sickle cell disease. Mediterr J Hematol Infect Dis. 2018;10:e2018032. https://doi.org/10.4084/mjhid.2018.032
  • Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379:373-83. https://doi.org/10.1016/S0140-6736(11)60283-3
  • Piga A, Serra M, Longo F, et al. Changing patterns of splenectomy in transfusion-dependent thalassemia patients. Am J Hematol. 2011;86:808-10. https://doi.org/10.1002/ajh.22102
  • Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (Hb S) allele and sickle cell disease: a HuGE review. Am J Epidemiol. 2000;151:839-45. https://doi.org/10.1093/oxfordjournals.aje.a010288
  • National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: expert panel report. Washington, DC: National Institutes of Health, 2014.
  • McCurdy PR, Sherman AS. Irreversibly sickled cells and red cell survival in sickle cell anemia: a study with both DF32P and 51CR. Am J Med. 1978;64:253-8. https://doi.org/10.1016/0002-9343(78)90053-0
  • Eadie GS, Brown IW. Analytical review: red blood cell survival studies. Blood. 1953;8:1110-36.
  • Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sicklecell disease. Nat Med. 2002;8:1383-9. https://doi.org/10.1038/nm1202-799
  • Lancaster JR. Reaping of nitric oxide by sickle cell disease. Proc Natl Acad Sci. 2002;99:552-3. https://doi.org/10.1073/pnas.032633399
  • Robinson JM, Lancaster JR Jr. Hemoglobin-mediated, hypoxia-induced vasodilation via nitric oxide: mechanism(s) and physiologic versus pathophysiologic relevance. Am J Respir Cell Mol Biol. 2005;32:257-61. https://doi.org/10.1165/rcmb.F292
  • Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;2:104. https://doi.org/10.1038/ncomms1104
  • Schnog JB, Duits AJ, Muskiet FA, ten Cate H, Rojer RA, Brandjes DP. Sickle cell disease; a general overview. Neth J Med. 2004;62:364-74.
  • Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480-7. https://doi.org/10.2471/BLT.06.036673
  • Arcasoy A. Dünya’da ve Türkiye’de talasemi ve hemoglobinopatiler. Hemoglobinopati ve Talasemi ÖnlemTanı-Tedavi Ulusal Hemoglobinopati Konseyi Sağlık Bakanlığı. 2003;2:11-9, Antalya.
  • Canatan D, Aydınok Y. Talasemi ve Hemoglobinopatiler. Tanı ve Tedavi; Retma Matbaacılık Antalya, 2007; 11-19.
  • Kılınç Y, Akmanlar N, Kümi M, Köker I. The incidences of hemoglobinopathies and thalassemias in cord blood of newborns from Çukurova Province. Med Bull. 1992;25:9-14.
  • Al-Mulhim AS, Alshehri MH. Laparoscopic cholecystectomy in adult patients with sickle cell disease. Surg Laparosc Endosc Percutan Tech. 2012;22:454-8. https://doi.org/10.1097/SLE.0b013e3182619408
  • Delatte SJ, Hebra A, Tagge EP, et al. Acute chest syndrome in the postoperative sickle cell patient. J Pediatr Surg. 1999;34:188-92. https://doi.org/10.1016/S0022-3468(99)90254-3
  • Howard J. Sickle cell disease: when and how to transfuse. Am Soc Hematol Educ Prog. 2016;2:625-31. https://doi.org/10.1182/asheducation-2016.1.625
  • Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. Blood Rev. 2013;27:279-87. https://doi.org/10.1016/j.blre.2013.09.001
  • Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-22. https://doi.org/10.1056/NEJM199505183322001
  • Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033-48. https://doi.org/10.1001/jama.2014.10517
  • Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995;333:206-13. https://doi.org/10.1056/NEJM199507273330402
  • Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Am Soc Hematol Educ Prog. 2013;2013:439-46. https://doi.org/10.1182/asheducation-2013.1.439
  • Alotaibi GS, Alsaleh K, Bolster L, Sean McMurtry M, Wu C. Preoperative transfusion in patients with sickle cell disease to prevent perioperative complications: A systematic review and meta-analysis. Hematology. 2014;19:463-71. https://doi.org/10.1179/1607845414Y.0000000158
  • Koshy M, Weiner SJ, Miller ST, Sleeper LA, Vichinsky E, Brown AK, et al. Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. Blood. 1995;86:3676-84.
  • Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. The Lancet. 2013;381:930-8. https://doi.org/10.1016/S0140-6736(12)61726-7
  • Al-Jaouni S, Al-Muhayawi S, Qari M, Nawas MA, AbdelRazeq H. The safety of avoiding transfusion preoperatively in patients with sickle cell hemoglobinopathies. Blood. 2002;100:1-9.
  • Edwin F, Aniteye E, Tettey M, et al. Hypothermic cardiopulmonary bypass without exchange transfusion in sickle-cell patients: a matched-pair analysis. Interact Cardiovasc Thorac Surg. 2014;19:771-6. https://doi.org/10.1093/icvts/ivu249
  • Roizen MF. Anesthesia implications of concurrent diseases. In: Miller RD, ed. Anesthesia. 5th ed. Philadelphia: Chuchill Livingstone, 2000.
  • Fisher B, Roberts CS. Tourniquet use and sickle cell hemoglobinopathy: how should we proceed?. South Med J. 2010;103:1156-60. https://doi.org/10.1097/SMJ.0b013e3181efaf3b
  • Giardine B, Borg J, Higgs DR, et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet. 2011;43:295-301. https://doi.org/10.1038/ng.785
  • Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411-6. https://doi.org/10.1182/blood.V97.11.3411
  • C. Staikou, E. Stavroulakis, Karmaniolou I. A narrative review of peri-operative management of patients with thalassaemia. Anaesthesia. 2014;69:494-510. https://doi.org/10.1111/anae.12591
  • Firth PG. Anesthesia and hemoglobinopathies. Anesthesiol Clin. 2009;27:321-36. https://doi.org/10.1016/j.anclin.2009.05.001
  • Akar N, Çavdar AO, Dessi E, Loi A, Pirastu M, Cao A. β-thalassemia mutations in the Turkish population. J Med Genet. 1987;24:378-9. https://doi.org/10.1136/jmg.24.6.378
  • Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40-7. https://doi.org/10.1196/annals.1345.006
  • Abi Saad GS, Musallam KM, Taher AT. The surgeon and the patient with b-thalassaemia intermedia. Br J Surg. 2011;98:751-60. https://doi.org/10.1002/bjs.7533
  • Orr D. Difficult intubation: a hazard in thalassaemia. A case report. Br J Anaesth. 1967;39:585-6. https://doi.org/10.1093/bja/39.7.585
  • Ali S, Khan FA. Anaesthetic management of two patients with beta-thalassaemia intermedia. J Pak Med Assoc. 2010;60:582-4.
  • Voyagis GS, Kyriakis KP. Homozygous thalassemia and difficult endotracheal intubation. Am J Hematol. 1996;52:125-6. https://doi.org/10.1002/(SICI)1096- 8652(199606)52:2<125::AID-AJH15>3.0.CO;2-G
  • Perez JA, Padilla J, Rodriguez MA, Cura S, et al. Splenectomy in a patient with beta thalassemia intermedia and severe hemolytic anemia. Rev Esp Anestesiol Reanim. 2001;48:288-91.
  • Suwanchinda V, Tengapiruk Y, Udomphunthurak S. Hypertension perioperative splenectomy in thalassemic children. J Med Assoc Thai. 1994;77:66-70.
  • Taher A, Isma’eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96:488-91. https://doi.org/10.1160/TH06-05-0267
  • Butwick A, Findley I, Wonke B. Management of pregnancy in a patient with b thalassaemia major. Int J Obstet Anesth. 2005;14:351-4. https://doi.org/10.1016/j.ijoa.2005.02.002
  • Katz R, Goldfarb A, Muggia M, Gimmon Z. Unique features of laparoscopic cholecystectomy in beta thalassemia patients. Surg Laparosc Endosc Percutan Tech. 2003;13:318-21. https://doi.org/10.1097/00129689-200310000-00006
  • Perez Ferrer A, Ferrazza V, Gredilla E, Buendia JV, Rua A, Larrea A. Bloodless surgery in a patient with thalassemia minor. Usefulness of erythropoietin, preoperative blood donation and intraoperative blood salvage. Minerva Anestesiol. 2007;73:323-6.
  • Waters JH, Lukauskiene E, Anderson ME. Intraoperative blood salvage during cesarean delivery in a patient with b thalassemia intermedia. Anesth Analg. 2003;97:1808-09. https://doi.org/10.1213/01.ANE.0000087046.91072.E8
  • Suwanchinda V, Tanphaichitr V, Pirayavaraporn S, Somprakit P, Laohapensang M. Hemodynamic responses to captopril during splenectomy in thalassemic children. J Med Assoc Thai. 1999;82:666-71.
APA ATICI Ş, OZDEMIR L (2019). Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. , 77 - 86. 10.5222/jarss.2019.25743
Chicago ATICI Şebnem,OZDEMIR LEVENT Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. (2019): 77 - 86. 10.5222/jarss.2019.25743
MLA ATICI Şebnem,OZDEMIR LEVENT Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. , 2019, ss.77 - 86. 10.5222/jarss.2019.25743
AMA ATICI Ş,OZDEMIR L Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. . 2019; 77 - 86. 10.5222/jarss.2019.25743
Vancouver ATICI Ş,OZDEMIR L Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. . 2019; 77 - 86. 10.5222/jarss.2019.25743
IEEE ATICI Ş,OZDEMIR L "Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?." , ss.77 - 86, 2019. 10.5222/jarss.2019.25743
ISNAD ATICI, Şebnem - OZDEMIR, LEVENT. "Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?". (2019), 77-86. https://doi.org/10.5222/jarss.2019.25743
APA ATICI Ş, OZDEMIR L (2019). Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. Anestezi Dergisi, 27(2), 77 - 86. 10.5222/jarss.2019.25743
Chicago ATICI Şebnem,OZDEMIR LEVENT Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. Anestezi Dergisi 27, no.2 (2019): 77 - 86. 10.5222/jarss.2019.25743
MLA ATICI Şebnem,OZDEMIR LEVENT Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. Anestezi Dergisi, vol.27, no.2, 2019, ss.77 - 86. 10.5222/jarss.2019.25743
AMA ATICI Ş,OZDEMIR L Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. Anestezi Dergisi. 2019; 27(2): 77 - 86. 10.5222/jarss.2019.25743
Vancouver ATICI Ş,OZDEMIR L Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?. Anestezi Dergisi. 2019; 27(2): 77 - 86. 10.5222/jarss.2019.25743
IEEE ATICI Ş,OZDEMIR L "Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?." Anestezi Dergisi, 27, ss.77 - 86, 2019. 10.5222/jarss.2019.25743
ISNAD ATICI, Şebnem - OZDEMIR, LEVENT. "Kalıtsal Hemoglobinopatilerde Zor Karar: Kan Transfüzyonu; Ne Zaman, Nasıl, Niçin?". Anestezi Dergisi 27/2 (2019), 77-86. https://doi.org/10.5222/jarss.2019.25743